Shares of Kura Oncology, Inc. (NASDAQ:KURA) have been assigned an average recommendation of “Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $18.30.

Several analysts have issued reports on the company. BidaskClub lowered Kura Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. Zacks Investment Research upgraded Kura Oncology from a “hold” rating to a “buy” rating and set a $17.00 price objective on the stock in a research note on Monday, October 2nd. ValuEngine lowered Kura Oncology from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Wedbush assumed coverage on Kura Oncology in a research note on Tuesday, December 26th. They issued a “buy” rating and a $19.00 price objective on the stock. Finally, Oppenheimer set a $18.00 price objective on Kura Oncology and gave the company a “buy” rating in a research note on Thursday, November 16th.

Large investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System grew its position in shares of Kura Oncology by 24.5% in the third quarter. California State Teachers Retirement System now owns 31,500 shares of the company’s stock valued at $471,000 after purchasing an additional 6,200 shares during the last quarter. Nationwide Fund Advisors grew its position in shares of Kura Oncology by 66.2% in the second quarter. Nationwide Fund Advisors now owns 25,758 shares of the company’s stock valued at $240,000 after purchasing an additional 10,258 shares during the last quarter. State of Wisconsin Investment Board acquired a new position in shares of Kura Oncology in the second quarter valued at approximately $102,000. Rhumbline Advisers acquired a new position in shares of Kura Oncology in the second quarter valued at approximately $131,000. Finally, Schwab Charles Investment Management Inc. grew its position in shares of Kura Oncology by 61.3% in the third quarter. Schwab Charles Investment Management Inc. now owns 39,200 shares of the company’s stock valued at $587,000 after purchasing an additional 14,900 shares during the last quarter. Hedge funds and other institutional investors own 64.26% of the company’s stock.

Shares of Kura Oncology (NASDAQ:KURA) opened at $15.50 on Thursday. Kura Oncology has a twelve month low of $5.75 and a twelve month high of $17.50. The stock has a market capitalization of $468.34 and a PE ratio of -10.00. The company has a current ratio of 13.48, a quick ratio of 13.48 and a debt-to-equity ratio of 0.07.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Tuesday, November 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.01). analysts expect that Kura Oncology will post -1.52 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Kura Oncology, Inc. (KURA) Receives Average Recommendation of “Buy” from Analysts” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/01/04/kura-oncology-inc-kura-receives-average-recommendation-of-buy-from-analysts.html.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.